HypomagnesemiaHypogamnesamiaNCT07089004
Hypomagnesemia and Its Clinical Outcome
An observational study of Hypomagnesemia and Critical Illness, run by Bangladesh Bioscience Research Group at 1 site in Bangladesh.
Trial summary
Magnesium is an essential electrolyte involved in numerous physiological processes, including maintaining cellular integrity, regulating muscle tone, supporting cardiovascular function, and modulating immune responses. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Hypomagnesemia, Critical Illness, Intensive Care Unit (ICU) Patients
- How many people
- 112 participants
- Where
- 1 siteBangladesh
- Study dates
- 1 Jun 2024to 25 Apr 2025
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Population will consist of critically ill adult patients admitted to the Intensive Care Unit (ICU) of a tertiary care hospital in Bangladesh. The study will include both male and female patients aged 18 years and above, irrespective of their underlying diagnosis, provided they meet the inclusion criteria. Patients will be assessed for serum magnesium levels (Hypo; Normo and Hyper) within 24 hours of ICU admission, along with relevant biochemical, hematological and clinical parameters. The study will exclude individuals with known end-stage renal disease on dialysis, those receiving magnesium supplementation prior to ICU admission, pregnant women and patients with incomplete medical records.
Who may be able to join
- Patients aged 18 years and above.
- Patients admitted to the Intensive Care Unit (ICU).
- Patients who have serum magnesium levels measured within 24 hours of ICU admission.
Who cannot join
- Patients with known end-stage renal disease on dialysis.
- Patients with a history of magnesium supplementation prior to ICU admission.
- Pregnant women.
- Patients with incomplete medical records or unavailable laboratory data.
Trial locations and contacts
1 site in 1 country.
Bangladesh1 site
University of Science and Technology Chittagong (USTC)
Chittagong, Khulshi, 4202
About this study
Official title: Co-relation of Hypomagnesemia With Clinical Outcomes in Critically Ill Patients Admitted to a Tertiary Care ICU in Bangladesh
Magnesium is an essential electrolyte involved in numerous physiological processes, including maintaining cellular integrity, regulating muscle tone, supporting cardiovascular function, and modulating immune responses. Despite its critical role, magnesium is often overlooked in clinical practice, earning it the title of the "forgotten electrolyte." Hypomagnesemia, defined as serum magnesium levels below 1.5 mEq/L, has been associated with adverse clinical outcomes such as increased mortality, prolonged ICU stays, and higher requirements for mechanical ventilation. Critically ill patients are particularly vulnerable to hypomagnesemia due to various underlying conditions, gastrointestinal losses, and renal complications. However, limited data are available from Bangladesh on the burden and clinical impact of hypomagnesemia in ICU settings. This study aims to assess the correlation between hypomagnesemia and clinical outcomes, including length of ICU stay, need for mechanical ventilation, and mortality among critically ill patients in a tertiary care ICU in Bangladesh.
- Being tested
- No intervention (observational study)
- Medical subject headings
- Critical Illness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No intervention (observational study)Diagnostic test
Observational - Biochemical, Hematological and Clinical Scoring Assessments
What is being measured
The primary outcome is the main question the study is designed to answer.
Association of Hypomagnesemia with ICU Mortality
To assess the relationship between low serum magnesium levels and all-cause mortality among critically ill ICU patients.
Measured: From the date of ICU admission until the date of ICU discharge or death, assessed up to 60 days.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2025
- Study start1 Jun 2024
- Primary completion31 Dec 2024
- Study completion25 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypomagnesemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 112 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Bangladesh Bioscience Research Group
- Sponsor type
- Research network
- Collaborators
- Chattogram International Dental College, Chittagong Medical College and Hospital, Bangladesh Medical University
- Responsible party
- Principal investigator, Pair Ahmed Jiko, Bangladesh Medical Research Council (BMRC)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07089004
- Sponsor's protocol ID
- BBMH/2023/RP-2342
- Other IDs
- BBMH/June/2023/011
- Acronym
- Hypogamnesamia
- Status last verified
- Jul 2025
- First submitted
- 29 Jun 2025
- Last updated
- 28 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual Participant Data (IPD) will not be shared with other researchers to ensure the protection of patient confidentiality and comply with institutional and ethical guidelines. Only aggregated, de-identified data may be shared upon reasonable request and with appropriate ethical approvals.
Study at a glance
From the registry record, last updated by the sponsor on 28 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Co-relation of Hypomagnesemia With Clinical Outcomes in Critically Ill Patients Admitted to a Tertiary Care ICU in Bangladesh
- ClinicalTrials.gov ID
- NCT07089004
- Acronym / sponsor ID
- Hypogamnesamia / BBMH/2023/RP-2342
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 112 participants (actual)
- Lead sponsor
- Bangladesh Bioscience Research GroupResearch network
- Collaborators
- Chattogram International Dental College, Chittagong Medical College and Hospital, Bangladesh Medical University
- Study start
- 1 Jun 2024 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 25 Apr 2025 (actual)
- First posted
- 28 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Magnesium is an essential electrolyte involved in numerous physiological processes, including maintaining cellular integrity, regulating muscle tone, supporting cardiovascular function, and modulating immune responses. Despite its critical role, magnesium is often overlooked in clinical practice, earning it the title of the "forgotten electrolyte." Hypomagnesemia, defined as serum magnesium levels below 1.5 mEq/L, has been associated with adverse clinical outcomes such as increased mortality, prolonged ICU stays, and higher requirements for mechanical ventilation. Critically ill patients are particularly vulnerable to hypomagnesemia due to various underlying conditions, gastrointestinal losses, and renal complications. However, limited data are available from Bangladesh on the burden and clinical impact of hypomagnesemia in ICU settings. This study aims to assess the correlation between hypomagnesemia and clinical outcomes, including length of ICU stay, need for mechanical ventilation, and mortality among critically ill patients in a tertiary care ICU in Bangladesh.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Population will consist of critically ill adult patients admitted to the Intensive Care Unit (ICU) of a tertiary care hospital in Bangladesh. The study will include both male and female patients aged 18 years and above, irrespective of their underlying diagnosis, provided they meet the inclusion criteria. Patients will be assessed for serum magnesium levels (Hypo; Normo and Hyper) within 24 hours of ICU admission, along with relevant biochemical, hematological and clinical parameters. The study will exclude individuals with known end-stage renal disease on dialysis, those receiving magnesium supplementation prior to ICU admission, pregnant women and patients with incomplete medical records.
Key inclusion criteria (3 listed)
- Patients aged 18 years and above.
- Patients admitted to the Intensive Care Unit (ICU).
- Patients who have serum magnesium levels measured within 24 hours of ICU admission.
Key exclusion criteria (4 listed)
- Patients with known end-stage renal disease on dialysis.
- Patients with a history of magnesium supplementation prior to ICU admission.
- Pregnant women.
- Patients with incomplete medical records or unavailable laboratory data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No intervention (observational study)Observational - Biochemical, Hematological and Clinical Scoring Assessments | Diagnostic test | – |
Primary outcome
Association of Hypomagnesemia with ICU Mortality
Time frame: From the date of ICU admission until the date of ICU discharge or death, assessed up to 60 days.
To assess the relationship between low serum magnesium levels and all-cause mortality among critically ill ICU patients.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jul 2025.
- Individual participant dataSharing planned: No. Individual Participant Data (IPD) will not be shared with other researchers to ensure the protection of patient confidentiality and comply with institutional and ethical guidelines. Only aggregated, de-identified data may be shared upon reasonable request and with appropriate ethical approvals.
Related trials for Hypomagnesemia
Active, not recruiting
Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy
Ovarian Carcinoma
Not yet recruiting
Magnesium Supplementation as a Nutritional Intervention in Sarcopenia
Sarcopenia
RecruitingObservational study
The Study of Urinary Biomarkers in Patients With Hypomagnesemia
Hypomagnesemia
RecruitingPhase 4
Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards
Hypomagnesemia
Not yet recruitingPhase 2
MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes Mellitus
Hypomagnesemia in Type 2 Diabetic Patients
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypomagnesemia and Critical Illness, run by Bangladesh Bioscience Research Group at 1 site in Bangladesh.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Association of Hypomagnesemia with ICU Mortality (time frame: From the date of ICU admission until the date of ICU discharge or death, assessed up to 60 days.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2025.